SOPHiA GENETICS (NASDAQ:SOPH) President Sells $13,888.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) President Ross Muken sold 2,800 shares of the firm’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total transaction of $13,888.00. Following the completion of the sale, the president owned 682,432 shares of the company’s stock, valued at approximately $3,384,862.72. The trade was a 0.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total value of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.

SOPHiA GENETICS Price Performance

Shares of SOPH traded up $0.05 during mid-day trading on Thursday, hitting $5.12. The company’s stock had a trading volume of 125,040 shares, compared to its average volume of 181,146. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm has a 50-day simple moving average of $4.74 and a 200 day simple moving average of $4.72. The firm has a market capitalization of $350.67 million, a P/E ratio of -10.04 and a beta of 1.04. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Analysts predict that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently bought and sold shares of the company. Savvy Advisors Inc. purchased a new position in SOPHiA GENETICS in the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Guggenheim raised their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research raised their price target on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Mount Sinai collaboration: Mount Sinai Health System will adopt SOPHiA’s AI-powered SOPHiA DDM™ platform to accelerate genomic testing and precision oncology research — a meaningful commercial reference that can drive platform adoption, revenue growth and credibility with other academic centers. Mount Sinai collaboration
• Positive Sentiment: Analyst support: Recent analyst activity includes price-target increases and buy ratings (e.g., Guggenheim and BTIG raising targets toward ~$7), which can attract demand from institutional and retail buyers.
• Neutral Sentiment: Insider selling under 10b5-1 plans: Several executives (CEO Jurgi Camblong, President Ross Muken, others) executed planned sales totaling roughly ~40k–45k shares to cover tax withholdings tied to vested awards. Trades were pre-arranged 10b5-1 sales, which typically reduces negative interpretation but still increases float in the short term. SEC Form 4 (CEO)
• Neutral Sentiment: Sector tailwind / industry validation: Coverage about Mount Sinai and other health systems using AI to speed genomic testing highlights growing market demand for AI-driven genomics platforms, supporting SOPH’s TAM and adoption case. HealthcareITNews
• Negative Sentiment: Recent fundamentals and profitability headwinds: SOPH reported a March quarter EPS miss (reported loss per share larger than consensus) and continues to show negative margins and ROE, which remain risks for near-term valuation and require revenue traction to justify higher targets. Quarterly results & profile

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.